Disclosures: Valerie Canva – Board Membership: ROCHE Philippe Mathurin – Board Membership: Schering-Plough, Janssen-Cilag, BMS, Gilead, Abvie; Consulting: Roche, Bayer, Boehringer Sebastien Dharancy – Board Membership: NOVARTIS; Speaking and Teaching: ASTELLAS, ROCHE The following people have nothing to disclose: Guillaume Lassailly, Franck Saint-Marcoux, Juliette Boulanger, Alexandre Louvet, Odile Goria, Stephanie Truant, Gilles Lebuffe, Emmanuel Boleslawski, Francois Rene Pruvot Rising alpha-fetoprotein (AFP) has been suggested to be a marker of poor prognosis after liver transplant (LT) for hepato-cellular carcinoma (HCC), but prior studies relied on only two

data points and were imprecise in assessing the AFP trend, and did not adequately Selleck RAD001 account for random fluctuations of AFP in liver disease. The primary aim of this study was to examine the association between AFP slope and post-LT HCC recurrence, with AFP slope more precisely estimated from multiple data points over time. Our cohort included

336 consecutive patients undergoing LT with MELD exception for HCC within Milan criteria between January 2003 and February 2013. Most (98%) had pre-LT loco-regional therapy (LRT). The AFP slope was estimated by fitting a regression line to the AFP levels over time. The median number of AFP data points was 6 (IQR 4-8) INCB024360 per patient and the median time interval was 64 days (IQR 36-97). The median post-LT follow-up was 4 years (range 2-6.2 years). The 1- and 5-year patient survival was 94% and 77%; and 1- and 5-year recurrence-free probabilities were 95% and 86%, respectively. In univariate analysis, significant predictors of HCC recurrence included microvascular invasion (HR 13.1, 95% CI 6.8-25.2, p<0.001), tumor grade (HR 1.8, 95% CI 1.3-2.5, p<0.001), pathologic stage MCE公司 > Milan criteria (HR 8.9, 95% CI 3.9-20.6,

p< 0.001), 3 tumor nodules (HR 5.4, 95% CI 2.2-13.4, p=0.002), AFP slope >7.5 ng/mL/ month (HR 3.9, 95% CI 1.5-10.2, p=0.005), and female gender (HR 2.3, 95% CI 1.2-4.3, p=0.01). AFP at diagnosis at all cutoffs (>100, >300, >400, >500, and >1000 ng/mL), age, race, liver disease diagnosis, waitlist time and number of LRT were not significant predictors of HCC recurrence. When only pre-transplant variables were included in multivariate analysis, 3 tumor nodules (HR 7.7, 95% CI 3.0-20.1, p<0.001), AFP slope >7.5 ng/mL/month (HR 3.0, 95% CI 1.1-7.9, p=0.03), and female gender (HR 2.6, 95% CI 1.3-5.2, p=0.008) were significant predictors of HCC recurrence. Three tumor nodules and a rising AFP slope were associated with microvascular invasion; with AFP slope >7.5 ng/mL/month being the most significant (OR 6.2, CI 1.5-26.3, p=0.01). The 1- and 5-year survival without recurrence for the 23 patients (7%) with pre-LT AFP slope >7.5 ng/mL/month was 91% and 70%, respectively, versus 96% and 87% for all others (p=0.01). Conclusion: Rising AFP with slope >7.